RecruitingNot ApplicableNCT06850753

En Bloc Resection of the Liver and Pancreas With a "Non-touch" Technique Followed by Liver Transplantation to Improve the Overall Survival in Patients With Non-resectable Hilar Cholangiocarcinoma Beyond the Mayo Clinic Transplant Criteria

Superior Right Abdominal Excentration and Liver Transplantation (SURE-LT) for Perihilar Cholangiocarcinoma


Sponsor

Oslo University Hospital

Enrollment

15 participants

Start Date

Jan 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Surgery for hilar cholangiocarcinoma (phCCA) remains a significant challenge. The minority of patients who are eligible for resection are exposed to high procedure-related morbidity and mortality, and despite apparent R0 resection, cancer recurrence is common. The benefit of R1 resection compared to the best palliative chemotherapy has been questioned. The concept of extended surgery to achieve better radicality is controversial and in many instances, associated with higher procedure-related risk and unclarified oncological benefit. For unresectable patients, liver transplantation, per the Mayo protocol, remains the only alternative for a few patients. Optimal staging pre- and intraoperatively is problematic since only the local biliary ductal involvement and, to a certain extent, lymph node dissemination can be reasonably correctly assessed. The reliability and validity of the intraoperative frozen section have been questioned. Furthermore, microscopic tumor cell affection leading to recurrent disease has been found in 16% of presumed N0 lymph nodes when analyzed by immunohistochemistry, and patients with nodal micrometastasis showed the same dismal survival as those with positive nodes on regular pathology (pN1). Taken together, there is a lack of good surgical options for patients with marginally or unresectable phCCA that do not satisfy current criteria for liver transplantation. The practical problem in the current surgical techniques for hilar cholangiocarcinoma, particularly in locally advanced disease, is that the hepatoduodenal ligament, in most instances, represents an incompletely staged operative field, making the probability of obtaining true free margins uncertain. An alternative procedure must, therefore, consider the anatomical and multidimensional pattern of dissemination and the limitations in the accurate staging of phCCA, and this suggests that a wider surgical margin is needed to obtain radical resection in locally advanced phCCA. The aim of the current study is tho these the following hypothesis: Locally advanced hilar cholangiocarcinoma without M1 lymph node metastatic disease can be radically resected by extending the surgical margin to include the complete hepatobiliary axis and the main anatomical trajectories of local and regional dissemination through an "en-bloc" surgical approach. M1 metastatic disease is defined as positive nodes in the following locations at staging: * Station 9: lymph nodes around the celiac axis. * Station 14: lymph nodes along the superior mesenteric artery or vein. * Station 15: lymph nodes along the middle colic vein. * Station 16: para-aortic lymph nodes. Patients will be treated by chemotherapy and radiation therapy with an observation period of at least 6 months showing response or stable disease before final inclusion. The operative procedure consists of a superior right abdominal exenteration, including the liver, pancreas, spleen, and vena cava + liver transplantation. If islets are available from the same donor, this will be administered postoperatively according to the institutional protocol. Main enpoint is overall survival at 1, 3 and 5 years


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a highly complex surgical procedure for patients with hilar cholangiocarcinoma (a bile duct cancer located at the junction of the bile ducts in the liver) that cannot be removed by standard surgery and does not meet current liver transplant criteria. The procedure involves removing the liver and part of the pancreas together followed by a liver transplant. **You may be eligible if...** - You have been confirmed (or strongly suspected based on imaging and elevated CA 19-9 tumor marker) to have perihilar cholangiocarcinoma (bile duct cancer near the liver) - Your cancer is considered unresectable (cannot be removed by standard surgery) - You do not have lymph node involvement or distant spread - If you have primary sclerosing cholangitis (PSC), you had a prior complete resection more than 24 months ago without residual disease **You may NOT be eligible if...** - You have confirmed lymph node metastases or distant spread - You have significant underlying liver disease that makes transplantation too risky - You have had a prior surgical resection less than 24 months ago Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURELiver transplantation after en bloc resection of the liver and pancreas

Exenteration of the upper right part of the abdomen, including the liver and pancreas en bloc in locally advanced hilar cholangiocarcinoma, followed by liver transplantation


Locations(1)

Oslo University Hospital

Oslo, Norway

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06850753


Related Trials